SCHEMBL1898563

SCHEMBL1898563

Cc1ccc(-c2cc(C(=O)Nc3nnc(-c4ccco4)o3)c3cccc(C)c3n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 7/20 0.67
RAB9A P51151 3/20 0.60
NPC1 O15118 2/20 0.60
LMNA P02545 7/20 0.58
ALOX12 P18054 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
KMT2A Q03164 1/20 0.56
KDM4E B2RXH2 4/20 0.50
TP53 P04637 1/20 0.50
ALOX15 P16050 1/20 0.50
HTT P42858 1/20 0.50
POLB P06746 2/20 0.49
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
LCLAT1 Q6UWP7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1902098 0.94 STAT3 (0.76) STAT3RAB9ANPC1LMNAALOX12
SCHEMBL1898648 0.87 STAT3 (0.87) STAT3RAB9ANPC1LMNAALOX12
SCHEMBL1898262 0.85 STAT3 (0.75) STAT3RAB9ANPC1LMNAALOX12
SCHEMBL1905492 0.83 STAT3 (0.76) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1897448 0.82 STAT3 (0.81) STAT3RAB9ANPC1LMNAALOX12
SCHEMBL1904403 0.81 STAT3 (0.82) STAT3RAB9ANPC1LMNAALOX12
SCHEMBL1900858 0.81 STAT3 (0.70) STAT3RAB9ANPC1LMNAALOX12
SCHEMBL1905389 0.81 STAT3 (0.72) STAT3RAB9ANPC1LMNAALOX12
SCHEMBL29382140 0.80 STAT3 (1.00) STAT3RAB9ANPC1LMNASMN1; SMN2
SCHEMBL1899809 0.80 STAT3 (1.00) STAT3RAB9ANPC1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325181-B1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) 2017-03-29 EP disclosed
US-8466290-B2 STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2013-06-18 US disclosed
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) 2011-07-14 US disclosed
EP-2325181-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT Pharma Ip General Incorporated Association (JP) 2011-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172429-A1 STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT STAT3, STAT4, STAT5B STAT3 1/4885RAB9A 2148/4885NPC1 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.